Chen R, Petrazzini B, Duffy A, Rocheleau G, Jordan D, Bansal M
Genome Biol. 2025; 26(1):50.
PMID: 40065360
PMC: 11892324.
DOI: 10.1186/s13059-025-03518-5.
Azimi F, Khakpour G, Sedaghat A, Mostafaiee F, Kasraei H, Naseripour M
J Curr Ophthalmol. 2025; 36(2):205-209.
PMID: 40012800
PMC: 11856112.
DOI: 10.4103/joco.joco_53_24.
Wang M, He L, Yan P
Sci Rep. 2025; 15(1):5645.
PMID: 39955364
PMC: 11830035.
DOI: 10.1038/s41598-025-90211-z.
Kim K, Han M, Lee D
Comput Struct Biotechnol J. 2025; 27:333-345.
PMID: 39897058
PMC: 11782887.
DOI: 10.1016/j.csbj.2025.01.003.
Zhang H, Gao M, Wang H, Zhang J, Wang L, Dong G
Sci Rep. 2025; 15(1):4015.
PMID: 39893238
PMC: 11787394.
DOI: 10.1038/s41598-025-86977-x.
Ameliorative effects of root and rhizome extract on high fat diet‑induced obesity in mice through regulation of the SIRT1/PGC1α/AMPK pathways in muscle and liver tissues.
Lyu C, Kang S, Shao H, Kim D, Jung H
Mol Med Rep. 2025; 31(3).
PMID: 39886968
PMC: 11795245.
DOI: 10.3892/mmr.2025.13440.
A phenotype-based AI pipeline outperforms human experts in differentially diagnosing rare diseases using EHRs.
Mao X, Huang Y, Jin Y, Wang L, Chen X, Liu H
NPJ Digit Med. 2025; 8(1):68.
PMID: 39875532
PMC: 11775211.
DOI: 10.1038/s41746-025-01452-1.
Advancing long-read nanopore genome assembly and accurate variant calling for rare disease detection.
Negi S, Stenton S, Berger S, Canigiula P, McNulty B, Violich I
Am J Hum Genet. 2025; 112(2):428-449.
PMID: 39862869
PMC: 11866955.
DOI: 10.1016/j.ajhg.2025.01.002.
Skeletal muscle disorders as risk factors for type 2 diabetes.
Tammineni E, Manno C, Oza G, Figueroa L
Mol Cell Endocrinol. 2025; 599:112466.
PMID: 39848431
PMC: 11886953.
DOI: 10.1016/j.mce.2025.112466.
Genetic mapping of serum metabolome to chronic diseases among Han Chinese.
Cheng C, Xu F, Pan X, Wang C, Fan J, Yang Y
Cell Genom. 2025; 5(2):100743.
PMID: 39837327
PMC: 11872534.
DOI: 10.1016/j.xgen.2024.100743.
Population Genomics of Premature Termination Codons in Cavefish With Substantial Trait Loss.
Roback E, Ferrufino E, Moran R, Shennard D, Mulliniks C, Gallop J
Mol Biol Evol. 2025; 42(2).
PMID: 39833658
PMC: 11796094.
DOI: 10.1093/molbev/msaf012.
Impact of rare non-coding variants on human diseases through alternative polyadenylation outliers.
Zou X, Zhao Z, Chen Y, Xiong K, Wang Z, Chen S
Nat Commun. 2025; 16(1):682.
PMID: 39819850
PMC: 11739498.
DOI: 10.1038/s41467-024-55407-3.
Genomic characterization of Huntington's disease genetic modifiers informs drug target tractability.
Namuli K, Slike A, Hollebeke M, Wright G
Brain Commun. 2025; 7(1):fcae418.
PMID: 39801710
PMC: 11724427.
DOI: 10.1093/braincomms/fcae418.
Specifying cellular context of transcription factor regulons for exploring context-specific gene regulation programs.
Minaeva M, Domingo J, Rentzsch P, Lappalainen T
NAR Genom Bioinform. 2025; 7(1):lqae178.
PMID: 39781510
PMC: 11704787.
DOI: 10.1093/nargab/lqae178.
An integrative analysis reveals cancer risk associated with artificial sweeteners.
Xie J, Zhu Y, Yang Z, Yu Z, Yang M, Wang Q
J Transl Med. 2025; 23(1):32.
PMID: 39780215
PMC: 11708064.
DOI: 10.1186/s12967-024-06047-0.
CDPMF-DDA: contrastive deep probabilistic matrix factorization for drug-disease association prediction.
Tang X, Hou Y, Meng Y, Wang Z, Lu C, Lv J
BMC Bioinformatics. 2025; 26(1):5.
PMID: 39773275
PMC: 11708303.
DOI: 10.1186/s12859-024-06032-w.
Leveraging cancer mutation data to inform the pathogenicity classification of germline missense variants.
Haque B, Cheerie D, Pan A, Curtis M, Nalpathamkalam T, Nguyen J
PLoS Genet. 2025; 21(1):e1011540.
PMID: 39761285
PMC: 11737861.
DOI: 10.1371/journal.pgen.1011540.
A Comprehensive Bioinformatics Approach to Analysis of Variants: Variant Calling, Annotation, and Prioritization.
Koroglu M, Bilguvar K
Methods Mol Biol. 2025; 2889:207-233.
PMID: 39745615
DOI: 10.1007/978-1-0716-4322-8_15.
Establishing age-group specific reference intervals of human salivary proteome and its preliminary application for epilepsy diagnosis.
Xue N, Xia X, Wang Y, Li X, Zheng N, Wang Y
Sci China Life Sci. 2024; 68(3):809-824.
PMID: 39731663
DOI: 10.1007/s11427-024-2730-6.
Yishen paidu pills attenuates 5/6 nephrectomy induced kidney disease via inhibiting the PI3K/AKT/mTOR signaling pathway.
Liu S, Cao Y, Yuan Q, Xie Y, Zhu Y, Yao L
Front Pharmacol. 2024; 15:1510098.
PMID: 39669205
PMC: 11634598.
DOI: 10.3389/fphar.2024.1510098.